KEYNOTE-024

Pembrolizumab in PD-L1–High Advanced NSCLC

Paziente / Popolazione Intervento / Esposizione Confronto Esito

In 305 patients with stage IV NSCLC and PD-L1 TPS ≥50%, no EGFR/ALK alterations, pembrolizumab improved progression-free and overall survival compared with platinum-doublet chemotherapy.

305

Disegno

Open-label RCT

Esito

BICR-assessed PFS

Rilevanza

RisultatoPFS 10.3 vs 6.0 months (HR 0.50). 5-yr OS 31.9% vs 16.3%.

Reck M, et al. N Engl J Med. 2016;375(19):1823-1833. 10.1056/NEJMoa1606774

Discussione e critica

First single-agent checkpoint-inhibitor approval as first-line therapy in lung cancer. Strict PD-L1-high selection (TPS ≥50%) — do not generalise.